The Oncology Institute Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________________
Form
__________________________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported)
___________________________________
(Exact name of registrant as specified in its charter)
___________________________________
| (State or other jurisdiction of incorporation) |
(Commission File Number) | (I.R.S. Employer Identification No.) |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area
code:
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act.
Item 5.07. Submission of Matters to a Vote of Security Holders.
On May 7, 2025, The Oncology Institute, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “2025 Annual Meeting”) in which the Company’s stockholders considered three proposals, each of which is described in more detail in the Company’s Definitive Proxy Statement, filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 27, 2025.
At the meeting, a total of 61,891,379 shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”) were voted, representing 81.70% of the 75,753,229 shares of Common Stock outstanding as of the March 17, 2025 record date. The results of the items voted on at the 2025 Annual Meeting are as follows:
Proposal 1: Election of Directors
The Company’s stockholders elected eight directors to serve for the ensuing year and until their successors are elected and qualified, or until their earlier death, resignation or removal. The Company elects its directors on a plurality vote basis. The votes regarding the election of directors were as follows:
| Nominee | For | Authority Withheld | Broker Non-Votes | |||
| Richard Barasch | 39,183,430 | 654,584 | 22,053,365 | |||
| Brad Hively | 35,152,238 | 4,685,776 | 22,053,365 | |||
| Karen Johnson | 34,449,869 | 5,388,145 | 22,053,365 | |||
| Mohit Kaushal | 39,297,684 | 540,330 | 22,053,365 | |||
| Gabriel Ling | 35,197,055 | 4,640,959 | 22,053,365 | |||
| Anne McGeorge | 39,243,506 | 594,508 | 22,053,365 | |||
| Mark Pacala | 39,243,514 | 594,500 | 22,053,365 | |||
| Daniel Virnich | 39,773,654 | 64,360 | 22,053,365 | |||
Proposal 2: Ratification of the Appointment of Independent Registered Public Accountants
The ratification of the appointment of BDO USA, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025 was approved. The votes regarding the ratification of the appointment were as follows:
| For | Against | Abstain | Broker Non-Votes | |||
| 61,175,079 | 682,121 | 34,179 | N/A |
Proposal 3: Approval to amend the Company’s Third Amended and Restated Certificate of Incorporation to effect a reverse stock split if deemed appropriate by the Company’s Board of Directors (the “2025 Reverse Stock Split Proposal”)
The 2025 Reverse Stock Split Proposal was approved. The amendment to the Company’s Third Amended and Restated Certificate of Incorporation to effect a reverse stock split at a ratio of between 1-for-5 and 1-for-40 will only be filed in the event the Board of Directors deems it to be necessary and appropriate within one year of the 2025 Annual Meeting. The votes regarding the approval of the 2025 Reverse Stock Split Proposal were as follows:
| For | Against | Abstain | Broker Non-Votes | |||
| 59,269,880 | 2,621,458 | 41 | N/A |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Dated: May 8, 2025 | THE ONCOLOGY INSTITUTE, INC. | |
| By: | /s/ Mark Hueppelsheuser | |
| Mark Hueppelsheuser General Counsel |
||